Please provide your email address to receive an email when new articles are posted on . Syndromes of extreme insulin resistance include generalized or partial lipodystrophy and insulin receptor ...
The U.S. Food and Drug Administration has approved Myalept, metreleptin for injection, as a treatment option for patients with congenital generalized or acquired generalized lipodystrophy.
The MarketWatch News Department was not involved in the creation of this content. Entos Pharmaceuticals Awarded $4 Million USD in Funding from the California Institute for Regenerative Medicine (CIRM) ...
Researchers at UT Southwestern Medical Center have discovered the first molecular biomarker for acquired generalized lipodystrophy (AGL), a rare disorder in which fat deposits are destroyed, causing ...
Regeneron’s New Phase 3 Study on Mibavademab: A Potential Game-Changer for Generalized Lipodystrophy
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Regeneron Pharmaceuticals is conducting a ...
SAN DIEGO--(BUSINESS WIRE)--Entos ® Pharmaceuticals (Entos), a clinical-stage genetic medicines company committed to using its Fusogenix™ PLV™ technology to develop cures and improve the lives of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback